侖伐替尼是目前晚期肝癌一線標準靶向治療藥物,其機制獨特、療效與安全性俱佳,不管是單藥還是聯合方案在晚期肝癌領域均佔據着重要治療地位。2020年國家醫保目錄更新,侖伐替尼被納入醫保目錄可謂衆望所歸,這意味着患者自付比例將大幅度降低,真正實現了讓好藥更大程度地用於中國晚期肝癌患者一線治療。參考資料:[1] 4585:Clinical Value of Atezolizumab+Bevacizumab for First-Line Unresectable Hepatocellular Carcinoma(HCC):ANletwork Meta-Analysis,2020,ASCO.[2] ESMO asia:Imbrave 150-presented by Dr Ann-Lll Cheng(LBA-3)[3] Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163-1173. doi:10.1016/S0140-6736(18)30207-1[4] Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390. doi:10.1056/NEJMoa0708857[5] Chen LT, Martinelli E, Cheng AL, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31(3):334-351. doi:10.1016/j.annonc.2019.12.001[6] 4519 :A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC). First Author: Andrew X. Zhu,Massachusetts General Hospital Cancer Center and Jiahui International Cancer Center, Boston, MA,2020 ASCO Annual Meeting Proceedings[7] https://clinicaltrials.gov/ct2/show/NCT02576509